Aptose Biosciences Announces Completion of Acquisition by Hanmi Pharmaceutical | APTOF Stock News
Aptose Presents 86% CRc and 86% MRD-negativity in TUSCANY AML Triplet Trial
Aptose Biosciences Announces Update on Anticipated Timing of Closing of the Plan of Arrangement with Hanmi Pharmaceutical | APTOF Stock News
Aptori Launches Autonomous Offensive Testing to Eliminate the AI-Driven Security Backlog
Aptose Shareholders Approve Hanmi Acquisition and Re-Domiciling
APTOSE BIOSCIENCES INC | 10-K: FY2025 Revenue: USD 0